p38 kinase inhibitors for the treatment of arthritis and osteoporosis: thienyl, furyl, and pyrrolyl ureas.
Inhibitors of the MAP kinase p38 are potentially useful for the treatment for osteoporosis, arthritis, and other inflammatory diseases. A series of thienyl, furyl, and pyrrolyl ureas has been identified as potent p38 inhibitors, displaying in vitro activity in the nanomolar range.
Redman
A M
AM
Department of Chemistry Research, Bayer Research Center, Pharmaceutical Division, West Haven, CT 06516, USA. aniko.redman.b@bayer.com
Johnson
J S
JS
Dally
R
R
Swartz
S
S
Wild
H
H
Paulsen
H
H
Caringal
Y
Y
Gunn
D
D
Renick
J
J
Osterhout
M
M
Kingery-Wood
J
J
Smith
R A
RA
Lee
W
W
Dumas
J
J
Wilhelm
S M
SM
Housley
T J
TJ
Bhargava
A
A
Ranges
G E
GE
Shrikhande
A
A
Young
D
D
Bombara
M
M
Scott
W J
WJ
D001168:Arthritis / Q000188:drug therapy*; D004791:Enzyme Inhibitors / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use*; D005663:Furans / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D020128:Inhibitory Concentration 50; D015850:Interleukin-6 / Q000378:metabolism; D020928:Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors*; D015394:Molecular Structure; D010024:Osteoporosis / Q000188:drug therapy*; D011758:Pyrroles / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D013876:Thiophenes / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D014407:Tumor Cells, Cultured; D014508:Urea / Q000031:analogs & derivatives*; D048051:p38 Mitogen-Activated Protein Kinases; D000093242:Interleukin-6 Inhibitors
D004791:Enzyme Inhibitors; D005663:Furans; D015850:Interleukin-6; D020928:Mitogen-Activated Protein Kinases; D011758:Pyrroles; D013876:Thiophenes; D014508:Urea; D048051:p38 Mitogen-Activated Protein Kinases; D000093242:Interleukin-6 Inhibitors